Literature DB >> 15380254

Activity of daptomycin against multi-resistant Gram-positive bacteria including enterococci and Staphylococcus aureus resistant to linezolid.

A P Johnson1, S Mushtaq, M Warner, D M Livermore.   

Abstract

The activity of daptomycin was assessed against 545 isolates of Gram-positive bacteria including enterococci, coagulase-positive and -negative staphylococci, beta-haemolytic streptococci, viridans streptococci and coryneforms. The panel of isolates was biased towards those with resistance to first-line antimicrobial agents and included linezolid-resistant enterococci and Staphylococcus aureus. MICs of daptomycin were < or =1mg/l for all the staphylococci, streptococci, and coryneforms, except for two isolates of Corynebacterium aquaticum, for which MICs were 8 mg/l. Daptomycin MICs were < or =2 and < or =4 mg/l for Enterococcus faecalis and Enterococcus faecium, respectively.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15380254     DOI: 10.1016/j.ijantimicag.2004.04.006

Source DB:  PubMed          Journal:  Int J Antimicrob Agents        ISSN: 0924-8579            Impact factor:   5.283


  9 in total

1.  In vitro synergy of daptomycin plus rifampin against Enterococcus faecium resistant to both linezolid and vancomycin.

Authors:  George Pankey; Deborah Ashcraft; Nalini Patel
Journal:  Antimicrob Agents Chemother       Date:  2005-12       Impact factor: 5.191

2.  Agents for the Treatment of Multidrug-resistant Gram-positive Endocarditis.

Authors:  Jennifer K Long
Journal:  Curr Infect Dis Rep       Date:  2005-07       Impact factor: 3.725

3.  Evaluation of standard- and high-dose daptomycin versus linezolid against vancomycin-resistant Enterococcus isolates in an in vitro pharmacokinetic/pharmacodynamic model with simulated endocardial vegetations.

Authors:  Ashley D Hall; Molly E Steed; Cesar A Arias; Barbara E Murray; Michael J Rybak
Journal:  Antimicrob Agents Chemother       Date:  2012-04-02       Impact factor: 5.191

4.  Multicenter evaluation of the Etest and disk diffusion methods for differentiating daptomycin-susceptible from non-daptomycin-susceptible Staphylococcus aureus isolates.

Authors:  Laura A Jevitt; Grace M Thorne; Maria M Traczewski; Ronald N Jones; John E McGowan; Fred C Tenover; Steven D Brown
Journal:  J Clin Microbiol       Date:  2006-09       Impact factor: 5.948

5.  Genetic modifications to temperate Enterococcus faecalis phage Ef11 that abolish the establishment of lysogeny and sensitivity to repressor, and increase host range and productivity of lytic infection.

Authors:  H Zhang; D E Fouts; J DePew; R H Stevens
Journal:  Microbiology (Reading)       Date:  2013-04-11       Impact factor: 2.777

6.  Daptomycin susceptibility of methicillin resistant Staphylococcus aureus (MRSA).

Authors:  Rajneet Kaur; Vikas Gautam; Pallab Ray; Gagandeep Singh; Lipika Singhal; Rupinder Tiwari
Journal:  Indian J Med Res       Date:  2012-10       Impact factor: 2.375

7.  Susceptibility of Glycopeptide-Resistant Enterococci to Linezolid, Quinupristin/dalfopristin, Tigecycline and Daptomycin in a Tertiary Greek Hospital.

Authors:  Sofia Maraki; George Samonis; Dimitra Dimopoulou; Elpis Mantadakis
Journal:  Infect Chemother       Date:  2014-12-29

8.  Clinical Characteristics of Methicillin-resistant Coagulase-negative Staphylococcal Bacteremia in a Tertiary Hospital.

Authors:  Koichi Yamada; Hiroki Namikawa; Hiroki Fujimoto; Kiyotaka Nakaie; Etsuko Takizawa; Yasuyo Okada; Akiko Fujita; Hiroyoshi Kawaguchi; Yasutaka Nakamura; Junko Abe; Yukihiro Kaneko; Hiroshi Kakeya
Journal:  Intern Med       Date:  2017-04-01       Impact factor: 1.271

9.  Daptomycin antimicrobial activity tested against methicillin-resistant staphylococci and vancomycin-resistant enterococci isolated in European medical centers (2005).

Authors:  Helio S Sader; Amy A Watters; Thomas R Fritsche; Ronald N Jones
Journal:  BMC Infect Dis       Date:  2007-04-18       Impact factor: 3.090

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.